Divergent Modulation of Nociception by Glutamatergic and GABAergic Neuronal Subpopulations in the Periaqueductal Gray

Vijay K. Samineni,1,5 Jose G. Grajales-Reyes,1,2,3,5 Bryan A. Copits,1,5 Daniel E. O’Brien,1,3,5 Sarah L. Trigg,1,5 Adrian M. Gomez,1 ©Michael R. Bruchas,1,4,5 and ©Robert W. Gereau IV1,5

Abstract

The ventrolateral periaqueductal gray (vPAG) constitutes a major descending pain modulatory system and is a crucial site for opioid-induced analgesia. A number of previous studies have demonstrated that glutamate and GABA play critical opposing roles in nociceptive processing in the vPAG. It has been suggested that glutamatergic neurotransmission exerts antinociceptive effects, whereas GABAergic neurotransmission exerts pronociceptive effects on pain transmission, through descending pathways. The inability to exclusively manipulate subpopulations of neurons in the PAG has prevented direct testing of this hypothesis. Here, we demonstrate the different contributions of genetically defined glutamatergic and GABAergic vPAG neurons in nociceptive processing by employing cell type-specific chemogenetic approaches in mice. Global chemogenetic manipulation of vPAG neuronal activity suggests that vPAG neural circuits exert tonic suppression of nociception, consistent with previous pharmacological and electrophysiological studies. However, selective modulation of GABAergic or glutamatergic neurons demonstrates an inverse regulation of nociceptive behaviors by these cell populations. Selective chemogenetic activation of glutamatergic neurons, or inhibition of GABAergic neurons, in vPAG suppresses nociception. In contrast, inhibition of glutamatergic neurons, or activation of GABAergic neurons, in vPAG facilitates nociception. Our findings provide direct experimental support for a model in which excitatory and inhibitory neurons in the PAG bidirectionally modulate nociception.

Key words: chemogenetics; Descending modulation; DREADDs; PAG; pain; RVM

Introduction

The periaqueductal gray (PAG), an evolutionarily conserved neurosubstrate in the midbrain, regulates a wide of complex behaviors, including pain (Basbaum and Fields, 1978; Graeff et al., 1993; Behbehani, 1995; Bandler and Keay, 1996; Holstege, 2014; Tovote et al., 2016;
Watson et al., 2016). The ventrolateral PAG (vlPAG) is a major site of endogenous opioid-induced pain suppression (Reynolds, 1969; Liebeskind et al., 1973; Mayer and Liebeskind, 1974; Hosobuchi et al., 1977; Baskin et al., 1986; Fields, 2004). The robust modulatory role of the vlPAG on spinal nociceptive processing is mediated by descending projections from the vlPAG via the rostral ventromedial medulla (RVM; Liebeskind et al., 1973; Basbaum and Fields, 1979; Bennett and Mayer, 1979; Hayes et al., 1979; Beitz et al., 1983; Duggan and Morton, 1983; Watkins et al., 1983; Morton et al., 1984; Moreau and Fields, 1986; Morgan et al., 1989; Urban and Smith, 1994; Pertovaara et al., 1996; Waters and Lumb, 1997; Antal and Odeh, 1998; Budai and Fields, 1998; Odeh and Antal, 2001; Maione et al., 2006; Waters and Lumb, 2008).

Previous studies have suggested that the vlPAG has a bidirectional role in the modulation of nociception. Non-specific activation of vlPAG neurons produces analgesia, whereas inhibition of vlPAG produces hyperalgesia to noxious stimulation (Reynolds, 1969; Liebeskind et al., 1973; Moreau and Fields, 1986; Depaulis et al., 1987; Siegfried and de Souza, 1989). It is tempting to speculate that output from the vlPAG has a purely analgesic action. However, the vlPAG comprises diverse subpopulations of neurons with distinct neurochemical properties that regulate excitatory and inhibitory neurotransmission (Behbehani and Fields, 1979; Moss and Basbaum, 1983; Moss et al., 1983; Moreau and Fields, 1986; Behbehani et al., 1990; Behbehani, 1995; Vaughan et al., 1997; Hahm et al., 2011; Ho et al., 2013). Microinjection of glutamate receptor agonists or GABA antagonists into the vlPAG leads to global activation of neurons and produces antinociceptive effects to noxious stimuli (Moreau and Fields, 1986; Ness and Gebhart, 1987; Carstens et al., 1988; Jacquet, 1988; Jones and Gebhart, 1988; Jensen and Yaksh, 1989; Sandkühler et al., 1989; Carstens et al., 1990; Budai and Fields, 1998; Morgan et al., 2003). In contrast, microinjecting glutamatergic antagonists or GABA agonists, presumably leading to global suppression of neural activity in the vlPAG, produces hyperalgesia (Moreau and Fields, 1986; Depaulis et al., 1987; Siegfried and de Souza, 1989; Behbehani et al., 1990). These studies suggest that in the context of a noxious stimulus, GABAergic neurotransmission in the vlPAG is pronociceptive, although the source of the GABAergic inputs to the vlPAG cannot be determined (Reichling and Basbaum, 1990a, 1990b). Collectively, a large number of prior studies suggest that glutamatergic and GABAergic neurons within the vlPAG play critical and complex roles in processing nociception (Behbehani and Fields, 1979; Moreau and Fields, 1986; Milian et al., 1987; Sandkühler et al., 1989; Siegfried and de Souza, 1989; Vaughan et al., 1997). Based on these studies, the vlPAG GABA disinhibition hypothesis has been proposed (Basbaum and Fields, 1978; Fields, 2004; Lau and Vaughan, 2014). In this hypothesis, GABAergic interneurons exert tonic inhibition over vlPAG glutamatergic neurons, which are thought to be output neurons that project to the RVM to facilitate the descending inhibition of nociception (Vaughan et al., 1997; Budai and Fields, 1998; Wang and Wessendorf, 2002; Maione et al., 2006; Starowicz et al., 2007; Heinricher et al., 2009; Park et al., 2010; Toyote et al., 2016). Despite the wealth of evidence supporting this model, the distinct roles of GABAergic and glutamatergical neuronal populations in descending vlPAG pain modulation have not been directly investigated. In this study, we use cell type-specific chemogenetic manipulations of neuronal activity in the vlPAG to test the hypothesis that GABAergic neurons are pronociceptive and glutamatergical neurons are antinociceptive.

Materials and Methods

Animals

All experiments were conducted in accordance with the National Institutes of Health guidelines and with approval from the Animal Care and Use Committee of Washington University School of Medicine. Male, 8- to 12-week-old, heterozygous Slc32a1tm2L°/tm2L° (Vgat-Cre, selectively targets Vgat™ GABAergic inhibitory neurons), Slc17a6tm2L°/tm2L° (Vglut2-Cre, selectively targets Vglut2™ glutamatergic excitatory neurons), and C57BL/6J mice were used (Vong et al., 2011). Mice were purchased from Jackson Laboratories (C57BL/6J, Vgat Cre, stock number 016962 and Vglut2 Cre stock number 016963) and colonies were established in our facilities. Experimenter were blind to treatment and genotype.

Viral constructs and surgery

Adeno-associated viruses (AAV8) were used to achieve Cre-independent chemogenetic vector expression: hM3Dq-mCherry (rAAV8/hSyn-hM3Dq-mCherry; 3.2 × 1012 particles/ml), hM4Di-mCherry (rAAV8/hSyn-hM4Di-mCherry; 2 × 1012 particles/ml), and control eGFP (rAAV8/hSyn-eGFP; 8 × 1012 particles/ml). Adeno-associated viruses (AAV5) were used to achieve Cre-dependent vector expression: hM3Dq-mCherry (rAAV5/hSyn-hM3Dq-mCherry; 6 × 1012 particles/ml), hM4Di-mCherry (rAAV5/hSyn-hM4Di-mCherry; 6 × 1012 particles/ml), and control eGFP (rAAV5/hSyn-eGFP; 3.4 × 1012 particles/ml). All viral vectors were acquired from the University of North Carolina Vector Core Facility. Before surgery, mice were anesthetized with isoflurane and secured in a stereotactic frame (David Kopf Instruments). A small midline dorsal incision was per-
formed to expose the skull and bilateral viral injections were performed using the following coordinates: vIPAG, −4.8–4.9 mm from bregma, ±0.3–0.4 mm lateral from midline, and 2.7–2.9 mm ventral to skull. Injections of 150 nL of the desired viral vectors into the vIPAG were performed at a rate of 100 nL per 60 s.

Chemogenetic manipulation

Three weeks after viral injections, mice were injected intraperitoneally with clozapine N-oxide (CNO, BML-NS105 from Enzo life sciences) 60 min before beginning behavioral assessment, and data were collected between the second and third hour after injection. All baselines for thermal and mechanical sensitivity were recorded two weeks after the viral injections and one week before the CNO administration. The doses of CNO were chosen based on preliminary pilot experiments designed to determine the minimal dose needed to activate designer receptor exclusively activated by designer drugs (DREADD) receptors in the vIPAG of C57BL/6J mice, Vgat-ires-Cre and Vglut2-ires-Cre mice. We assessed the response of these different mouse lines to various doses of CNO to identify the minimal doses required to activate DREADDs (data not shown). In non-Cre-dependent studies, we administered 1 mg/kg CNO for both hM3Dq activation and hM4Di inhibition. In Vgat Cre mice, we administered 3 mg/kg CNO for both hM3Dq activation and hM4Di inhibition. In Vglut2 Cre mice, we administered 2 mg/kg CNO for both hM3Dq activation and hM4Di inhibition.

Pain behavior assessment

To evaluate nociception, mechanical withdrawal thresholds and thermal withdrawal latencies were assayed. Mice were tested for baseline responses to mechanical and thermal stimuli, as previously described (O’Brien et al., 2013). For the assessment of mechanical withdrawal threshold, von Frey filaments (North Coast Medical) were applied bilaterally to the hind paws of the mice using the up-down method. Two to three trials were performed on each hind paw for each mouse. The average 50% withdrawal threshold was calculated for each paw individually and then averaged to obtain a threshold value for each mouse. The Hargreaves test was performed to evaluate heat sensitivity thresholds, measuring latency of withdrawal to a radiant heat source (IITC Life Science, Model 390). We applied the radiant heat source bilaterally to the hind paw and measured the latency to evoke a withdrawal. Three to five replicates were acquired per hind paw per mouse, and values for both paws were averaged.

Electrophysiology

To determine the functional effects of chemogenetic manipulations in vIPAG neurons, we performed targeted whole-cell patch-clamp recordings in acute coronal slices from both Vgat- and Vglut2-Cre mice expressing either hM3Dq or hM4Di receptors. Mice used for electrophysiology and behavioral studies were between 8 and 12 weeks of age. Three weeks after viral infection of vIPAG neurons, coronal slices containing the vIPAG were prepared as previously described (Siuda et al., 2015). GABAergic and glutamatergic neurons in the vIPAG were visualized through a 40× objective using IR-differential interference contrast (DIC) microscopy on an Olympus BX51 microscope, and mCherry+ cells were identified using epifluorescent illumination with a green LED (530 nm; Thorlabs), coupled to the back fluorescent port of the microscope. Whole-cell recordings of vIPAG GABAergic and glutamatergic neurons expressing hM3Dq-mCherry and hM4Di-mCherry were performed using a Heka EPC 10 amplifier (Heka) with Patchmaster software (Heka). Following stable 5-min whole-cell recordings (baseline), the direct effects of either hM3Dq or hM4Di receptor expression on cellular excitability was isolated by blocking AMPA/KARs (10 μM NBQX, Abcam), NMDARs (50 μM D-APV, Abcam), GABA_ARs (100 μM picrotoxin, Abcam), and GABA_BRs (50 μM baclofen, Abcam). aCSF solution containing 10 μM CNO added to the antagonist cocktail above was bath applied to the brain slice.

Immunohistochemistry

To perform histologic confirmation of virus expression and injection sites, C57, Vgat Cre, and Vglut2 Cre mice expressing hM3Dq-mCherry, hM4Di-mCherry, and EGFP virus were deeply anesthetized with ketamine/xylazine cocktail at the end of every experiment and then perfused with 20 ml of PBS and 20 ml of a 4% paraformaldehyde PBS solution (PFA). Brains were removed, postfixed in 4% PFA overnight at 4°C, and then immersed in 30% sucrose for cryoprotection. Using a cryostat, 30-μm tissue sections were collected and stored in PBS, containing 0.4% sodium azide, at 4°C. After washing the sections in PBS 1×, we incubated the tissues in blocking solution containing 5% normal goat serum and 0.2% Triton X-100 PBS solution for 1 h at room temperature. Primary antibodies against mCherry (Mouse, Clontech 632392; 1:500) and GFP (rabbit polyclonal, Life Technologies A11122; 1:500) were diluted in blocking solution and incubated overnight at 4°C. After three 10-min washes, tissues were incubated for 1 h at room temperature with secondary antibodies [Life Technologies: Alexa Fluor 488 donkey anti rabbit IgG (1:300); Alexa Fluor 488 goat anti rabbit (1:300); Alexa Fluor 555 goat anti mouse (1:300); and Neurotrace (435/455nm, 1:500)]. Sections were mounted with Vectashield (H-1400) hard mounting media and imaged on a Nikon Eclipse 80i epifluorescence microscope.

Fluorescence in situ hybridization (FISH)

Following rapid decapitation of mice, brains were flash frozen in −50°C 2-methylbutane and stored at −80°C for further processing. Coronal sections containing the PAG, corresponding to the injection coordinates used in the behavioral experiments, were cut at 20 μm at −20°C and thaw-mounted onto Super Frost Plus slides (Fisher). Slides were stored at −80°C until further processing. FISH was performed according to the RNAScope 2.0 Fluorescent Multiple Kit User Manual for Fresh Frozen Tissue (Advanced Cell Diagnostics) as described previously (Wang et al., 2012). Slides containing PAG coronal brain sections were fixed in 4% PFA, dehydrated, and pre-treated with protease IV solution for 30 min. Sections were then incubated with target probes for mouse Vglut2 (slc17a6, accession number NM_080853.3, probe region
Adeno-associated virus type 8 (AAV8), Vgat (slc32a1, accession number NM_009508.2, probe region 894-2037), and Cre (accession number KC845567.1, probe region 1058-2032). All target probes consisted of 20 double Z oligonucleotides and were obtained from Advanced Cell Diagnostics. Following probe hybridization, sections underwent a series of probe signal amplification steps (AMP1-4) followed by incubation of fluorescent probes (Alexa Fluor 488, Atto 550, Atto 647), designed to target the specified channel associated with the probes. Slides were counterstained with 4′,6-diamidino-2-phenylindole (DAPI; RNAscope), and coverslips were mounted with Vectashield Hard Set mounting medium (Vector Laboratories). Images were obtained on a Leica TCS SPE confocal microscope (Leica), and Application Suite Advanced Fluorescence (LAS AF) software was used for analyses.

Statistics
Throughout the study, researchers were blinded to all experimental conditions. At least two to three replicate measurements were performed and averaged in all behavioral assays. The studies were designed to compare behavioral readouts following CNO to baseline values before CNO administration. This was done using paired t tests to account for interindividual variability among mice across different cohorts. The control eGFP group was included throughout our study to determine whether CNO administration or DREADD expression had off-target effects in the behaviors that we tested. All datasets were evaluated for normality using the D’Agostino and Pearson omnibus normality test. A parametric test was used only when normality was confirmed. If normality could not be confirmed, the nonparametric Wilcoxon matched pairs test was used.

Results
Global chemogenetic manipulation of viPAG activity suggests bidirectional modulation of nociceptive behaviors
We used a chemogenetic approach to investigate whether selectively manipulating activity of resident neurons in the viPAG can modulate different nociceptive modalities. DREADDs exploit selective expression of mutated muscarinic receptors that are responsive to an exogenously administered, normally inert ligand, CNO (Rogan and Roth, 2011). Adeno-associated virus type 8 (AAV8), carrying neuron-specific stimulatory (hM3Dq) or inhibitory (hM4Di) DREADD fused with mCherry, was microinjected bilaterally into the viPAG (Fig. 1A). Robust expression of DREADDs, restricted to the viPAG, was observed three weeks after AAV8/hSyn-hM3Dq-mCherry (Fig. 1B) or AAV8/hSyn-hM4Di-mCherry injection (Fig. 1C). In mice expressing the stimulatory DREADD (hM3Dq) in viPAG neurons, CNO (1 mg/kg, i.p.) injection resulted in a significant increase in paw withdrawal latencies (PWLs) to thermal stimulation compared with baseline PWLs before CNO administration but did not alter paw withdrawal thresholds (PWTs) to mechanical stimuli compared with baseline PWTs before CNO administration (Fig. 1E; \( t_{(10)} = 3.674, \ast\ast p < 0.0043, n = 11 \)); Fig. 1H; \( t_{(10)} = 0.3489, p = 0.73, n = 11 \)). On the other hand, in mice expressing the inhibitory DREADD (hM4Di) in viPAG neurons, CNO (1 mg/kg, i.p.) injection resulted in a significant decrease in PWLs and PWTs compared with baseline (Fig. 1F; \( t_{(11)} = 6.693, \ast\ast\ast p < 0.0001, n = 12 \)); Fig. 1I; \( p < 0.05, n = 11 \)), indicating development of thermal and mechanical hypersensitivity. To confirm that CNO administration did not have any off-target effects on PWLs and PWTs, control mice expressing eGFP were administered CNO (1 mg/kg), which had no effect on PWLs or PWTs when compared with baseline (Fig. 1D; \( t_{(11)} = 0.2572, p = 0.80, n = 12 \)); Fig. 1G, \( t_{(11)} = 0.2945, p = 0.77, n = 9 \)). Taken together, these findings demonstrate that globally activating viPAG neurons attenuates nociception, while inhibiting them potentiates nociception, consistent with prior studies using pharmacologic activation or inhibition of the viPAG neurons (Moreau and Fields, 1986; Carstens et al., 1988; Jones and Gebhart, 1988; Jensen and Yaksh, 1989; Siegfried and de Souza, 1989; Behbehani et al., 1990; Carstens et al., 1990; Vaughan et al., 1997; Budai and Fields, 1998; Morgan et al., 2003).

The role of viPAG GABAergic and glutamatergic neuronal populations in nociceptive processing
The viPAG is comprised of both inhibitory GABAergic and excitatory glutamatergic neurons, and we hypothesized that these neuronal populations differentially regulate nociceptive processing. Double-label RNA-FISH in the viPAG of c57-mice revealed that GABAergic neurons (Vgat transcripts) and glutamatergic neurons (Vglut2 transcripts) show no overlap in expression in the PAG and, thus, are distinct populations (Fig. 2A,B). To selectively test the functional contributions of viPAG GABAergic and glutamatergic neurons in modulating nociceptive behaviors, we used Vgat-ires-Cre and Vglut2-ires-Cre mice to target and manipulate the activity of GABAergic and glutamatergic neurons, respectively. To determine the specificity of Cre in targeting Vgat+ neurons in Vgat-ires-Cre mice or in targeting Vglut2+ neurons in the Vglut2-ires-Cre mice, we performed RNA-FISH using probes for Vgat, Vglut, and Cre in viPAG slices obtained from Vgat Cre and Vglut2 Cre mice. We observed 79 ± 4.1% of Vglut2+ transcripts in the viPAG colabel with Vglut2 Cre-expressing neurons, and 97.5 ± 2.5% Vglut2 Cre-expressing neurons in the viPAG colabel with Vglut2+ transcripts (Fig. 2C,E,J). We also observed 92 ± 4.5% of Vgat+ transcripts in the viPAG colabel with Vglut2 Cre-expressing neurons, and 95.5 ± 4.2% Vgat-Cre-expressing neurons in the viPAG colabel with Vgat+ transcripts (Fig. 2D,K,P). Our double-label RNA-FISH studies revealed that Vgat and Vglut2 Cre mice faithfully label viPAG GABAergic and Vglut2+ glutamatergic neuronal populations, as described previously for other brain regions (Vong et al., 2011).

To selectively test the functional contributions of viPAG GABAergic and glutamatergic neurons in modulating nociceptive behaviors, we used Cre-dependent DREADD expression in Vgat-ires-Cre and Vglut2-ires-Cre mice to target GABAergic and glutamatergic neurons, respectively. Virus carrying Cre-dependent stimulatory (hM3Dq) or inhibitory (hM4Di) DREADDs fused with mCherry were....
injected into the vlPAG of Vgat-Cre mice or Vglut2-Cre mice. Three weeks after DREADD injection, we prepared acute coronal slices of the vlPAG from Vgat-Cre and Vglut2-Cre mice and targeted mCherry neurons in vlPAG for whole-cell recordings (Fig. 3A). hM3Dq-expressing vlPAG neurons were held at hyperpolarized membrane potentials, and a brief bath application of 10 μM CNO caused a transient depolarization and robust action potential firing in both Vgat

![Images and graphs related to the experiment and data analysis.]

**Figure 1.** Global chemogenetic manipulation of vlPAG activity suggests parallel bidirectional modulation of nociceptive behaviors. **A.** Constructs used in viral targeting of AAV8 hM3Dq–mCherry, AAV8 hM4Di–mCherry and AAV8–EGFP via bilateral injections into the vlPAG. **B, C.** Representative images of coronal sections containing vlPAG demonstrating restricted viral expression following microinjection of the AAV8 hM3Dq (**B**) and hM4Di (**C**) into the vlPAG. **D, G.** Relative to pretreatment baseline values, CNO (1 mg/kg, i.p.) did not have any significant effects on PWLs in mice expressing the control EGFP construct. **E, H.** CNO (1 mg/kg, i.p.) administration in hM3Dq-injected mice resulted in a significant increase in PWLs but not in PWTs. **F, I.** CNO (1 mg/kg, i.p.) administration in hM4Di-injected mice resulted in a significant decrease in PWLs and PWTs. *p < 0.05, **p < 0.005, ***p < 0.0001. Scale bars, 300 and 35 μm, 4X and 10X, respectively.
Figure 2. RNA-FISH demonstrates segregation of vPAG GABAergic and glutamatergic neurons and specificity of Cre in targeting Vgat- neurons in the Vgat-IRESCre mice or Vglut2- neurons in the Vglut2-IRESCre mice. A, Double RNA-FISH for Vgat (green) and Vglut2 (red) shows that GABAergic and glutamatergic neurons in the PAG are nonoverlapping populations. Scale bar, 200 μm. Counterstaining (blue) is DAPI. B, High-magnification image showing no colocalization of GABAergic and glutamatergic neurons in the PAG. Scale bar, 60 μm. C, 79 ± 4.1% of cells positive for Vglut2 transcripts in the vPAG colabel with Vglut2 Cre-expressing neurons, and 97.5 ± 2.5% of Vglut2 Cre-expressing neurons in the vPAG colabel with Vglut2 transcripts (N = 2 mice). D, 92 ± 4.5% of cells positive for Vgat transcripts in the vPAG colabel with Vgat Cre-expressing neurons, and 95.5 ± 4.2% of Vgat Cre-expressing neurons in the vPAG colabel with Vgat transcripts (N = 2 mice). E–G, Double RNA-FISH for Vglut2 (red) and Cre (green) shows extensive colocalization of Vglut2 transcripts with Cre-expressing neurons in the vPAG obtained from Vglut2 Cre mice. Scale bar, 60 μm. H–J, High-magnification image shows extensive colocalization of Vglut2 transcripts with Cre-expressing neurons in the vPAG. Scale bar, 15 μm. K, M, Double RNA-FISH for Vgat (red) and Cre (green) shows extensive colocalization of Vgat transcripts with Cre-expressing neurons in the vPAG obtained from Vgat Cre mice. Scale bar, 60 μm. N–P, High-magnification image shows extensive colocalization of Vgat transcripts with Cre-expressing neurons in the vPAG. Scale bar, 15 μm.
and Vglut2 neurons (Fig. 3B). To test the effects of G_{i}-coupled inhibition with hM4Di, we monitored neuronal activity while holding cells with a depolarizing current injection, which elicited consistent action potential firing in both Vgat and Vglut2 neurons. Bath perfusion with 10 \mu M CNO resulted in prolonged membrane hyperpolarization and decreased firing of both cell types (Fig. 3C). Quantification of the CNO effects on membrane potential and input resistance in grouped Vgat and Vglut2 neurons (N = 8 for Vgat and Vglut2 neurons). E–I, Voltage traces showing responses to a hyperpolarizing current of -20 pA and a depolarizing current injection of either 1 \times rheobase (purple traces) or 2 \times rheobase (blue traces) in both Vgat (E, H) and Vglut2 (F, I) neurons. In hM3Dq-expressing neurons, bath application of CNO elicited increased action potential firing in response to the same stimulus (E, H, green traces). In hM4Di neurons, CNO perfusion decreased neuronal excitability to suprathreshold stimuli. B, C, Scale bars, 20 mv and 10 s; E–I, Scale bars, 10 mv and 100 ms. All values are mean ± SEM.

We also investigated how CNO modulates membrane excitability in response to depolarizing step current injections. In hM3Dq-expressing neurons, we observed a large increase in the number of action potentials elicited during a 1 \times rheobase current following CNO stimulation in slices from both Vgat- and Vglut2-Cre mice (Fig. 3E,F). Suprathreshold current injections of 2 \times rheobase elicited sustained high-frequency action potential firing in both neuronal subtypes (Fig. 3F,I, blue traces), and CNO application dramatically reduced membrane excitability to an identical suprathreshold stimulus in mice injected with K^{+} channels (Stemson and Roth, 2014; Urban and Roth, 2015; Fig. 3D,G).
hM4Di constructs (Fig. 3F,I, green traces). This confirmed that we are able to bi-directionally modulate GABAergic and glutamatergic neuron excitability in the vPAG using hM3Dq and hM4Di DREADDs, and led us to explore the contributions of these neuronal populations in nociceptive processing.

To assess how vPAG GABAergic neurons contribute to nociceptive processing, we introduced Cre-dependent viral constructs containing either hM3Dq or hM4Di fused to mCherry or control virus lacking the DREADDs (hSyn-DIO-eGFP) into the vPAG of Vglut2-IRES-Cre mice (Fig. 4A). Three weeks after viral infection of vPAG neurons, restricted expression of the DREADD vectors was observed in neurons within the vPAG (Fig. 4B,C). Cre-dependent (3 mg/kg, i.p.) activation of vPAG GABAergic neurons via hM3Dq resulted in a significant decrease in PWLs to a noxious thermal stimulus (Fig. 4E; $t_{(9)} = 4.403, p = 0.0023, n = 9$) and PWTs to a mechanical stimulus (Fig. 4H; $p = 0.0469, n = 7$) compared with baseline. In contrast, CNO-induced (3 mg/kg, i.p.) inhibition of vPAG GABAergic neurons expressing hM4Di resulted in a significant increase in PWLs to noxious thermal stimulation compared with baseline (Fig. 4F; $t_{(13)} = 2.459, p = 0.0287, n = 14$) but did not have a significant effect on PWTs to mechanical stimuli compared with baseline (Fig. 4I; $t_{(11)} = 0.5885, p = 0.5681, n = 12$). CNO (3 mg/kg, i.p.) administration did not affect PWLs or PWTs in control mice expressing DIO-eGFP when compared with baseline (Fig. 4D; $t_{(9)} = 1.837, p = 0.8584, n = 10$) and (Fig. 4G; $t_{(9)} = 0.2055, p = 0.8423, n = 9$). Taken together, these results demonstrate that activation of GABAergic vPAG neurons results in hypersensitivity to mechanical and noxious thermal stimuli, while inhibiting the activity of GABAergic vPAG neurons decreases sensitivity to noxious heat only.

To directly examine the role of vPAG glutamatergic neurons in nociceptive processing, Cre-dependent viral constructs carrying hM3Dq-mCherry, hM4Di-mCherry, or a control virus (hSyn-DIO-eGFP) were injected bilaterally into the vPAG of Vglut2-IRES-Cre mice (Fig. 5A). Three weeks after injection, we observed robust DREADD expression restricted to the vPAG (Fig. 5B,C). Chemogenetic activation of vPAG Vglut2 neurons expressing hM3Dq with CNO (2 mg/kg, i.p.) significantly increased PWLs to thermal stimuli compared with baseline (Fig. 5E; $t_{(11)} = 2.375, p = 0.0368, n = 12$) but did not significantly alter PWTs to mechanical stimuli compared with baseline (Fig. 5H; $t_{(9)} = 0.8779, p = 0.405, n = 9$). To further examine the functional role of intrinsic activity of vPAG Vglut2 neurons, we administered CNO (2 mg/kg, i.p.) to inhibit vPAG Vglut2 neurons expressing hM4Di. This resulted in a significant decrease...
in PWLs to a noxious heat stimulus compared with baseline (Fig. 5F; n = 6, paired t test, p = 0.0313) and a decrease in PWTs to a mechanical stimulus compared with baseline (Fig. 5I; n = 6, paired t test, p = 0.0211). Control virus-injected mice showed no alterations in PWLs or PWTs on CNO (2 mg/kg, i.p.) administration compared with baseline (Fig. 5D; t(9) = 0.2897, p = 0.7786, n = 10; Fig. 5G, p = 1, n = 6). These results demonstrate that vlPAG Vglut2 neurons exert tonic control over thermal and mechanical nociceptive processing.

**Discussion**

Here, we report that global chemogenetic activation of vlPAG neurons attenuates thermal nociception while inhibiting vlPAG neurons causes thermal and mechanical hypersensitivity. Using cell type-specific chemogenetic manipulations, we found that activating GABAergic, or inhibiting glutamatergic, neurons in vlPAG, causes thermal and mechanical hypersensitivity. In contrast, inhibiting GABAergic or activating glutamatergic neurons attenuates thermal sensitivity but has no effect on mechanical sensitivity. The differential effects on thermal and mechanical sensitivity suggest that distinct circuit elements within the vlPAG regulate these two sensory modalities. These results provide new insights into the functional role of GABAergic and glutamatergic neurons in the vlPAG in the modulation of nociception.

The vlPAG is known to be an essential component of neural pathways that mediate stimulation and stress-induced analgesia (Reynolds, 1969; Yeung et al., 1977; Jones and Gebhart, 1988; Morgan et al., 1989; Hohmann et al., 2005; Samineni et al., 2011). Consistent with these previous studies, we found that global chemogenetic activation of vlPAG neurons produced antinociceptive effects. We also show that chemogenetic inhibition of vlPAG neurons leads to nociceptive hypersensitivity, consistent with a bidirectional role of the vlPAG in the modulation of nociception (Moreau and Fields, 1986; Depaulis et al., 1987; Heinricher et al., 1987; Ness and Gebhart, 1987; Carstens et al., 1988; Jacquet, 1988; Jones and Gebhart, 1988; Jensen and Yaksh, 1989; Siegfried and de Souza, 1989; Behbehani et al., 1990; Carstens et al., 1990). The magnitude of antinociceptive effects observed after global chemogenetic activation of vlPAG neurons is modest relative to the robust effects produced by electrical stimulation of the PAG or by microinjection of morphine, GABAA receptor antagonists, or glutamate agonists into the vlPAG (Reynolds, 1969; Liebeskind et al., 1973; Moreau and Fields, 1986; Depaulis et al., 1987; Ness and Gebhart, 1987; Carstens et al., 1988; Sandkühler et al., 1989; Siegfried and de Souza, 1989; Carstens et al., 1990). Such a difference could be expected if the number of neurons that are transduced with stimulatory DREADDs...
is small relative to the large number of neurons impacted by electrical or pharmacologic approaches.

Although the vPAG has been extensively studied for its role in endogenous descending pain modulation (Reynolds, 1969; Liebeskind et al., 1973; Basbaum and Fields, 1978; Sandkühler et al., 1989; Behbehani et al., 1990; Vaughan et al., 1997; McGarvaughty et al., 2003; Starowicz et al., 2007; Morgan et al., 2008; Waters and Lumb, 2008; Heinricher et al., 2009; Samineni et al., 2011; Wang et al., 2012; Ho et al., 2013; Lau and Vaughan, 2014; Tovote et al., 2016), previous studies have not yet determined how distinct subpopulations of vPAG neurons modulate pain transmission. Inhibitory neurotransmission in the vPAG is known to modulate nocifensive behaviors, since microinjecting a GABA agonist produces pronociceptive effects, while decreasing inhibitory neurotransmission by microinjection of a GABA antagonist into the vPAG produces antinociceptive effects to noxious stimuli (Moreau and Fields, 1986; Depaulis et al., 1987; Sandkühler et al., 1989; Budai and Fields, 1998; Morgan et al., 2003). Such studies led some to propose the vPAG GABA disinhibition analgesia hypothesis (Basbaum and Fields, 1978; Fields, 2004). Corroborating this hypothesis, many studies have shown that mu opioid receptor agonists have direct inhibitory effects on GABAergic neurons of vPAG. This causes analgesia when directly administered into the vPAG, suggesting that inhibition of GABAergic vPAG neuronal activity may be a major mechanism for opioid-induced analgesia (Chieng and Christie, 1996; Vaughan et al., 1997). The cellular mechanisms underlying the analgesic and hyperalgesic effects of manipulating inhibitory and excitatory neurotransmission in the vPAG have not been directly evaluated (Moreau and Fields, 1986; Carstens et al., 1988; Jacquet, 1988; Sandkühler et al., 1989; Vaughan et al., 1997; Budai and Fields, 1998; Fields, 2004; Maione et al., 2006; Starowicz et al., 2007). It is not known how distinct neuron subpopulations in the vPAG engage complex downstream circuits of the descending pain modulation pathway. For the first time, we show that chemogenetic activation of vPAG GABAergic neurons causes hypersensitivity to nociceptive stimuli while their inhibition causes antinoceception, consistent with the proposed role of GABAergic vPAG neurons in pain modulation.

It has been hypothesized that GABAergic interneurons exert tonic inhibition of vPAG glutamatergic neurons, which are thought to be output neurons that project to the RVM (Jacquet, 1988; Roychowdhury and Fields, 1996; Vaughan et al., 1997; Wang and Wessendorf, 2002; Morgan et al., 2008; Park et al., 2010; Hahn et al., 2011; Ho et al., 2013). These glutamatergic neurons have been hypothesized to play a role in an analgesic modulatory pathway (McGarvaughty et al., 2003; Maione et al., 2006; Starowicz et al., 2007), but this has not been selectively demonstrated. In agreement with the GABA disinhibition hypothesis, our RNA-FISH studies show that GABAergic and glutamatergic neurons in the PAG are distinct populations. We also found that chemogenetic activation of vPAG glutamatergic neurons is antinociceptive, whereas chemogenetic inhibition of these neurons is pronociceptive. Conversely, chemogenetic activation of GABAergic neurons in the vPAG produces hypersensitivity while inhibition of these neurons produces analgesia.

Surprisingly, we find that activation of vPAG glutamatergic neurons or inhibition of GABAergic neurons attenuated thermal but not mechanical sensitivity. While there are several possible explanations for this finding, we propose the hypothesis that distinct populations of inhibitory neurons regulate mechanical and thermal nociceptive modulatory pathways emanating from the vPAG. Here, we posit the presence of tonically active GABAergic neurons regulating descending pathways for thermal nociception, while the population regulating mechanical nociceptive modulation might by quiescent. This would explain the difference in effects of activating GABAergic neurons or inhibiting glutamatergic neurons on mechanical nociception. It is possible that the differences in the effects of DREADD-dependent regulation are simply due to the basal state of the neurons in question. That is, if the neurons are quiescent at baseline, then activation of a Gq-coupled DREADD might not affect descending modulation. Similarly, a neuron that is firing at a relatively high frequency at baseline might not be further stimulated by a Gq-coupled DREADD. Future studies are necessary to determine the differences in neuronal populations and circuits that code for mechanical versus thermal sensitivity. It is also possible that these results are simply due to a ceiling effect in our von Frey measurements. That is, that von Frey testing is not able to detect analgesic effects at baseline. We do not favor this hypothesis, as treatment with analgesic drugs can indeed increase PWTs in mice (Anseloni and Gold, 2008).

We believe that our results should not be interpreted as absolute, and we recognize that the behavioral changes that we report should not be attributed to the entirety of either the Vgat or Vglut2 vPAG neuronal populations. The PAG is comprised of molecularly diverse neuronal subpopulations that express fast neurotransmitters and/or neuropeptides (Mantyh, 1982; Moss and Basbaum, 1983; Moss et al., 1983; Smith et al., 1994). In the hypothalamus, recent genetic analysis of anatomically defined neurons has identified subpopulations that coexpress a variety of neuroactive substances that were previously thought to be exclusive to certain clusters (Romanov et al., 2017). Therefore, it is likely that vPAG GABAergic and glutamatergic neurons can be further subdivided into subpopulations based on their genetic identity and physiology. Although we have only attempted to dissect the roles of glutamatergic versus GABAergic vPAG neurons in pain modulation, future studies should examine the interplay between other neuronal populations within the vPAG that can be defined with the expression of other makers, such as neuropeptides, to assess their roles in regulating nociceptive processing.

While the stimulation of vPAG is predominantly associated with antinociceptive effects (Reynolds, 1969; Liebeskind et al., 1973; Carstens et al., 1988; Morgan et al., 1989; Sandkühler et al., 1989; Hohmann et al., 2005; Maione et al., 2006; Starowicz et al., 2007; Samineni et al., 2011), recent studies also identified facilitatory effects of the vPAG in
the maintenance of neuropathic pain (Pertovaara et al., 1996; Pertovaara et al., 1997; Heinricher et al., 2004; Guo et al., 2006; Lü et al., 2010). We show here that chemogenetic activation of GABAergic neurons or inhibition of glutamatergic neurons can lead to hypersensitivity to mechanical and thermal stimuli, suggesting that any disruption of the balance between activity of the vPAG excitatory and inhibitory neurons might contribute to the maintenance of chronic pain (Hahm et al., 2011; Ho et al., 2013; Lau and Vaughan, 2014). Future studies should explore the plastic changes in GABAergic and glutamatergic neurons that might contribute to the maintenance of chronic pain.

The vPAG has been shown to be instrumental in the descending modulation of pain processing. The vPAG is known to form strong connections with the RVM, and the locus coeruleus (Beitz et al., 1983; Behbehani, 1995; Antal and Odeh, 1998; Odeh and Antal, 2001; Bowman et al., 2013). Based on the data we present here, it will be of great interest to determine which of these, or other, projection targets mediate the differential modulation of nociception by glutamatergic and GABAergic projections from the vPAG.

References

Anseloni VC, Gold MS (2008) Inflammation-induced shift in the vulnerability of spinal GABA-A receptor-mediated modulation of nociception in the adult rat. J Pain 9:732–738. CrossRef Medline

Antal M, Odeh F (1998) The projections of the midbrain periaqueductal gray to serotonergic and noradrenergic nuclei of the pons and medulla oblongata in the rat. Eur J Neurosci 10:218–218. CrossRef Medline

Bandler R, Keay KA (1996) Columnar organization in the midbrain periaqueductal gray and the integration of emotional expression. Prog Brain Res 107:285–300. CrossRef Medline

Basbaum AI, Fields HL (1978) Endogenous pain control mechanisms: review and hypothesis. Ann Neurol 4:451–462. CrossRef Medline

Basbaum AI, Fields HL (1979) The origin of descending pathways in the dorsolateral funiculus of the spinal cord of the cat and rat: further studies on the anatomy of pain modulation. J Comp Neurol 187:513–531. CrossRef Medline

Baskin DS, Mehler WR, Hosobuchi Y, Richardson DE, Adams JE, Flitter MA (1986) Autopsy analysis of the safety, efficacy and cartography of electrical-stimulation of the central gray in humans. Brain Res 371:231–236. CrossRef Medline

Behbehani MM (1995) Functional characteristics of the midbrain periaqueductal gray. Prog Neurobiol 46:575–605. CrossRef Medline

Behbehani MM, Fields HL (1979) Evidence that an excitatory connection between the periaqueductal gray and nucleus raphé magnus mediates stimulation produced analgesia. Brain Res 170:85–93. CrossRef Medline

Behbehani MM, Jiang MR, Chandler SD, Ennis M (1990) The effect of GABA and its antagonists on midbrain periaqueductal gray neurones in the rat. Pain 40:195–204. CrossRef Medline

Beitz AJ, Mullett MA, Weiner LL (1983) The periaqueductal gray projections to the rat spinal trigeminal, raphe magnus, gigantocellular pars alpha and paragigantocellular nuclei arise from separate neurons. Brain Res 288:307–314. CrossRef Medline

Bennett GJ, Mayer DJ (1979) Inhibition of spinal cord interneurons by narcotic microinjection and focal electrical stimulation in the periaqueductal central gray matter. Brain Res 172:243–257. CrossRef Medline

Bowman BR, Kumar NN, Hassan SF, McMullan S, Goodchild AK (2013) Brain sources of inhibitory input to the rat rostral ventrolateral medulla. J Comp Neurol 521:213–232. CrossRef Medline

Budai D, Fields HL (1998) Endogenous opioid peptides acting at mu-opioid receptors in the dorsal horn contribute to midbrain modulation of spinal nociceptive neurons. J Neurophysiol 79:677–687. CrossRef Medline

Carstens E, Hartung M, Stelzer B, Zimmermann M (1990) Suppression of a hind-limb flexion withdrawal reflex by microinjection of glutamate or morphine into the periaqueductal gray in the rat. Pain 43:105–112. CrossRef Medline

Carstens E, Stelzer B, Zimmermann M (1988) Microinjections of glutamate or morphine at coincident midbrain sites have different effects on nociceptive dorsal horn neurons in the rat. Neurosci Lett 95:185–191. CrossRef Medline

Chieng B, Christie MD (1996) Local opioid withdrawal in rat single periaqueductal gray neurones in vitro. J Neurosci 16:7128–7136. CrossRef Medline

Depaulis A, Morgan MM, Liebeskind JC (1987) Gabaergic modulation of the analgesic effects of morphine microinjected in the ventral periaqueductal gray-matter of the rat. Brain Res 436:223–228. CrossRef Medline

Duggan AW, Morton CR (1983) Periaqueductal grey stimulation: an association between selective inhibition of dorsal horn neurones and changes in peripheral circulation. Pain 15:237–248. CrossRef Medline

Fields H (2004) State-dependent opioid control of pain. Nat Rev Neurosci 5:565–575. CrossRef Medline

Graeff FG, Silveira MC, Nogueira RL, Audi EA, Oliveira RM (1993) Role of the amygdala and periaqueductal gray in anxiety and panic. Behav Brain Res 58:123–131. CrossRef Medline

Guo W, Robbins MT, Wei F, Zou S, Dubner R, Ren K (2006) Supraspinal brain-derived neurotrophic factor signaling: a novel mechanism for descending pain facilitation. J Neurosci 26:126–137. CrossRef Medline

Hahn ET, Kim Y, Lee JJ, Cho YW (2011) GABAergic synaptic response and its opioidergic modulation in periaqueductal gray neurones of rats with neuropathic pain. BMC Neurosci 12:41. CrossRef Medline

Hayes RL, Price DD, Ruda M, Dubner R (1979) Suppression of nociceptive responses in the primate by electrical stimulation of the brain or morphine administration: behavioral and electrophysiological comparisons. Brain Res 167:417–421. CrossRef Medline

Heinricher MM, Cheng ZF, Fields HL (1987) Evidence for two classes of nociceptive modulating neurones in the periaqueductal grey. J Neurosci 7:271–278. CrossRef Medline

Heinricher MM, Martenson ME, Neubert MJ (2004) Prostaglandin E2 in the midbrain periaqueductal grey produces hyperalgesia and activates pain-modulating circuitry in the rostral ventromedial medulla. Pain 110:419–426. CrossRef Medline

Heinricher MM, Tavares I, Leith JL, Lumb BM (2009) Descending control of nociception: specificity, recruitment and plasticity. Brain Res Rev 60:214–225. CrossRef Medline

Ho YC, Cheng JK, Chiou LC (2013) Hypofunction of glutamatergic neurotransmission in the periaqueductal grey contributes to nerve-injury-induced neuropathic pain. J Neurosci 33:7825–7836. CrossRef Medline

Hohmann AG, Supilta RL, Bolton NM, Neely MH, Fegley D, Mangieri R, Krey JF, Walker JM, Holmes PV, Crystal JD, Duranti A, Tontini A, Mor M, Tarzia G, Piromelli D (2005) An endocannabinoid mechanism for stress-induced analgesia. Nature 435:1108–1112. CrossRef Medline

Holstege G (2014) The periaqueductal grey controls brainstem emotional motor systems including respiration. Prog Brain Res 209:379–405. CrossRef Medline

Hosobuchi Y, Adams JE, Linchitz R (1977) Pain relief by electrical stimulation of the central gray matter in humans and its reversal by naloxone. Science 197:183–186. CrossRef Medline

Jacquet YF (1988) The Nmda receptor - central role in pain inhibition in rat periaqueductal grey. Eur J Pharmacol 154:271–276. CrossRef Medline

Jensen TS, Yaksh TL (1989) Comparison of the antinociceptive effect of morphine and glutamate at coincidental sites in the periaqueductal gray. Brain Res 436:223–228. CrossRef Medline

Krey JF, Walker JM, Holmes PV, Crystal JD, Duranti A, Tontini A, Mor M, Tarzia G, Piromelli D (2005) An endocannabinoid mechanism for stress-induced analgesia. Nature 435:1108–1112. CrossRef Medline

March/April 2017, 4(2) e0129-16.2017 eNeuro.org
Urban DJ, Roth BL (2015) DREADDs (designer receptors exclusively activated by designer drugs): chemogenetic tools with therapeutic utility. Annu Rev Pharmacol Toxicol 55:399–417. CrossRef Medline

Urban MO, Smith DJ (1994) Localization of the antinociceptive and antianalgesic effects of neurotensin within the rostral ventromedial medulla. Neurosci Lett 174:21–25. CrossRef Medline

Vaughan CW, Ingram SL, Connor MA, Christie MJ (1997) How opioids inhibit GABA-mediated neurotransmission. Nature 390:611–614. CrossRef Medline

Vong L, Ye CP, Yang ZF, Choi B, Chua S, Lowell BB (2011) Leptin action on GABAergic neurons prevents obesity and reduces inhibitory tone to POMC neurons. Neuron 71:142–154. CrossRef Medline

Wang F, Flanagan J, Su N, Wang LC, Bui S, Nielsen A, Wu X, Vo HT, Ma XJ, Luo Y (2012) RNAscope: a novel in situ RNA analysis platform for formalin-fixed, paraffin-embedded tissues. J Mol Diagn 14:22–29. CrossRef Medline

Wang H, Wessendorf MW (2002) Mu- and delta-opioid receptor mRNAs are expressed in periaqueductal gray neurons projecting to the rostral ventromedial medulla. Neuroscience 109:619–634. CrossRef Medline

Waters AJ, Lumb BM (1997) Inhibitory effects evoked from both the lateral and ventrolateral periaqueductal grey are selective for the nociceptive responses of rat dorsal horn neurones. Brain Res 752:239–249. CrossRef Medline

Waters AJ, Lumb BM (2008) Descending control of spinal nociception from the periaqueductal grey distinguishes between neurons with and without C-fibre inputs. Pain 134:32–40. CrossRef Medline

Watkins LR, Young EG, Kinscheck IB, Mayer DJ (1983) The neural basis of footshock analgesia: the role of specific ventral medullary nuclei. Brain Res 276:305–315. CrossRef Medline

Watson TC, Cerminara NL, Lumb BM, Apps R (2016) Neural correlates of fear in the periaqueductal gray. J Neurosci 36:12707–12719. CrossRef Medline

Yeung JC, Yaksh TL, Rudy TA (1977) Concurrent mapping of brain sites for sensitivity to the direct application of morphine and focal electrical stimulation in the production of antinociception in the rat. Pain 4:23–40. CrossRef Medline